Rheumatoid arthritis is still expensive in the new decade: a comparison between two early RA cohorts, diagnosed 1996–98 and 2006–09
- 8 February 2016
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 45 (5) , 371-378
Abstract
Objectives: To calculate total costs during the first year after diagnosis in 463 patients with early rheumatoid arthritis (RA) included during 2006–09 (T2) and compare the results with a similar cohort included in 1996–98 (T1). Method: Clinical and laboratory data were collected regularly in both cohorts, and patients completed biannual questionnaires reporting health care utilization and number of days lost from work. Results: Disease activity was similar in both cohorts T1 and T2 at inclusion. Significant improvements were seen during the first year in both cohorts but were more pronounced in T2. Outpatient care increased and hospitalization decreased in T2 compared with T1. Almost 3% of patients had surgery in both cohorts, but in T2, only women had surgery. Drug costs were higher in T2 than in T1 (EUR 689 vs. EUR 435). In T2, 12% of drug costs were direct costs and 4% were total costs. The corresponding values for T1 were 9% and 3%. In T1, 50% were prescribed disease-modifying anti-rheumatic drugs (DMARDs) at inclusion, compared to T2, where prescription was > 90%. Direct costs were EUR 5716 in T2 and EUR 4674 in T1. Costs for sick leave were lower in T2 than in T1 (EUR 5490 vs. EUR 9055) but disability pensions were higher (EUR 4152 vs. EUR 2139), resulting in unchanged total costs. In T1, direct costs comprised 29% and indirect costs 71% of the total costs. The corresponding values for T2 were 37% and 63%. Conclusions: The earlier and more aggressive treatment of RA with traditional DMARDs in T2 resulted in better outcomes compared to T1. Direct costs were higher in T2, partly offset by decreased sick leave, but total costs remained unchanged.Keywords
Funding Information
- County Council in Östergötland
- Medical Research County Council of South-East Sweden
This publication has 31 references indexed in Scilit:
- Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trialAnnals of the Rheumatic Diseases, 2014
- Early rheumatoid arthritis 6 years after diagnosis is still associated with high direct costs and increasing loss of productivity: the Swedish TIRA projectScandinavian Journal of Rheumatology, 2013
- Costs of rheumatoid arthritis during the period 1990-2010: a register-based cost-of-illness study in SwedenRheumatology, 2013
- Consequences of inflammatory arthritis for workplace productivity loss and sick leave: a systematic reviewAnnals of the Rheumatic Diseases, 2013
- Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trialThe Lancet, 2012
- Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern SwedenAnnals of the Rheumatic Diseases, 2010
- Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritisArthritis Care & Research, 2009
- Economic consequences of established rheumatoid arthritis and its treatmentBest Practice & Research Clinical Rheumatology, 2007
- Infliximab treatment maintains employability in patients with early rheumatoid arthritisArthritis & Rheumatism, 2006
- Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project)Rheumatology, 2004